Blocking inhibitors of axon growth after spinal cord injury

Affiliations

¹ Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China. Electronic address: ronglm@mail.sysu.edu.cn.
² Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.

Comment

Limin Rong et al. Lancet Neurol. 2023 Aug.

. 2023 Aug;22(8):645-646.

doi: 10.1016/S1474-4422(23)00242-9.

¹ Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China. Electronic address: ronglm@mail.sysu.edu.cn.
² Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.

No abstract available

Conflict of interest statement

We declare no competing interests.

Soluble Nogo-Receptor-Fc decoy (AXER-204) in patients with chronic cervical spinal cord injury in the USA: a first-in-human and randomised clinical trial.
Maynard G, Kannan R, Liu J, Wang W, Lam TKT, Wang X, Adamson C, Hackett C, Schwab JM, Liu C, Leslie DP, Chen D, Marino R, Zafonte R, Flanders A, Block G, Smith E, Strittmatter SM. Maynard G, et al. Lancet Neurol. 2023 Aug;22(8):672-684. doi: 10.1016/S1474-4422(23)00215-6. Lancet Neurol. 2023. PMID: 37479373 Free PMC article. Clinical Trial.